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Data in longitudinal studies
Multiple biomarkers, e.g. blood pressure or CD4 counts, are
often collected repeatedly over time (longitudinal data)
time to an event of interest, e.g. death from any cause (survival
data)
Examples
• PSA repeated measures and time to a recurrence of prostate
cancer
• CD4 repeated measures and time to AIDS








• does treatment affect survival?
• are the average longitudinal evolutions different between males
and females?
Joint Analysis
• what is the effect of the longitudinal evolution of CD4 cell count in
the hazard rate for death?
• how the association between markers evolves over time (evolution
of the association)
• how marker-specific evolutions are related to each other
(association of the evolutions)
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Issues
Longitudinal studies are often affected by (informative) drop-out,
e.g. due to death: MCAR, MAR, MNAR
Biomarkers are often measured with error
Survival analysis assumes that covariates are measured without
error: Internal vs External covariates
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Principle































Longitudinal Marker (Y1) Time-To-Event (Y2)
If the two processes are associated⇒ define a model for their
joint probability distribution: f(y1, y2)
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Objectives of a joint analysis
explore the association between the two processes
describe the longitudinal process stopped by the event
predict the risk of event adjusted for the longitudinal
process
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Applications
Arose primarily in the field of AIDS, relating CD4 trajectories to
progression to AIDS in HIV+ patients (Faucett and Thomas, 1996)
Further developed in cancer, particularly modelling PSA levels
and their association with prostate cancer recurrence
(Proust-Lima and Taylor, 2009)







Joint Models to Analyse Longitudinal and Survival Data









• mixed effects model
• splines, etc.
• multiple markers of progression and/or different nature
• Gaussian, binary, Poisson
• continuous but non Gaussian
Survival model
• Relative risk model (Proportional hazard model)
• Accelerated failure time model
• Competing risks; recurrent events; multiple events
Linking structure
• depends on the purposes
• without consensus
• still evolving ...








Main families of joint models
Latent classes (Proust-Lima et al., 2012)
Shared parameters (Wulfsohn and Tsiatis, 1997; Henderson et al.,












How to specify the joint distribution, f(y1, y2)?
directly
factorize









f(y1, y2|b)f(b1, b2)db =
∫
f(y1|b1)f(y2|b2)f(b1, b2)db1db2














the mean level trajectory (linear mixed-effects model)
mi(t) = x>i (t)β1 + z>i (t)bi
random-effects
bi ∼ N (0,Σb)
more flexibility through polynomials or splines in xi and zi.








Estimates T ∗i , but using only Ti = min(T ∗i , Ci) and δi.
Assumes the following hazard model,
hi(t) = h0(t) exp{v>i β2 + γ ×mi(t)}
where h0(t) is the baseline hazard function (Weibull, piecewise
exponential, splines...)
vi is a vector of time-independent baseline covariates with an
associated vector of log hazard ratios, β2
γ ×mi(t) represents the linking structure.







How can we link longitudinal and survival data?
Use the observed baseline biomarker values
• We’re ignoring all the repeated measures and measurement error
Use the repeated measures as a time-varying covariate
• We’re still ignoring the measurement error
Model the longitudinal outcome, and use predictions as a
time-varying covariate
• Uncertainty in the longitudinal outcome is not carried through
Model both processes simultaneously in a joint model, defining a
joint probability distribution
• Reduce bias and maximize efficiency








What are the main characteristics of the longitudinal trajectory
associated with the Survival?
Current value parameterisation
hi(t) = h0(t) exp{v>i β2 + γ ×mi(t)}
Time-dependent slope
hi(t) = h0(t) exp{v>i β2 + γ1 ×mi(t) + γ2 ×m′i(t)}
 
 







Linking structure II – shared parameters
A time-independent association
Longitudinal submodel
mi(t) = (β0 + b0i) + (β1 + b1i)t
Survival submodel
hi(t) = h0(t) exp{v>i β2 + γ(b0i + b1i)}
hi(t) = h0(t) exp{v>i β2 + γ1b0i + γ2b1i}
random-effects: bi = (b0i, b1i) with density f(bi); usually a Gaussian







Linking structure III – random-effects
Random-effects parameterisation
mi(t) = (β0 + b0i) + (β1 + b1i)t
hi(t) = h0(t) exp{v>i β2 + γ(b2i)}
random-effects: bi = (b0i, b1i, b2i) with density f(bi); usually a
Gaussian














 p(Ti, δi|θ, bi)














 p(Ti, δi|θ, bi)
where




















 p(Ti, δi|θ, bi)
where






h0(u) exp{v>i β2 + γ ×mi(u)}du
}








Probably the most “marketable” feature of Joint Models
A growing interest in a tailored made medical decision
• Personalized Medicine
• Shared Decision Making
This is of high relevance in various diseases
• cancer research, cardiovascular diseases, HIV research ...
Bayesian approach
Physicians are interested in accurate prognostic tools that will inform
them about the future prospect of a patient to adjust medical care








Example: HIV/AIDS patients receiving HAART therapy
Interest in predicting survival probabilities for a new patient i that
has provided a set of CD4 measurements up to a specific time
point t
What do we know for the patient?
• a series of CD4 and/or viral load
• is event-free up to the last measurement
General Questions:
• Can we utilize CD4 or viral load measurements to predict survival?
• When to plan the next visit for a patient?
Survival probabilities and the visiting plan can be dynamically
updated as additional information is recorded - Dynamic
Predictions (Rizopoulos 2011)








Suppose a new individual data, D˜ = {y˜, T˜ = t, δ˜ = 0}
Future longitudinal values at time s > t
p(y˜(s) | D, D˜) =
∫∫
p(y˜(s)|D˜, b˜,θ) p(b˜|D˜,θ) p(θ|D)dθ db˜
Future survival probabilities at time s > t
p(T˜ ∗ > s | D, T˜ ∗ > t, y˜) =
∫∫
S˜(s | y˜, b˜)
S˜(t | y˜, b˜) p(b˜|D˜,θ) p(θ|D) dθ db˜








R - JM, joineR, frailtypack, INLA
WinBUGS, Stan, JMBayes
STATA - stjm command
Computationally intensive









parameterization = c("value", "slope", "both"),
method = c("weibull-PH-aGH", "weibull-PH-GH", "weibull-AFT-aGH",
"weibull-AFT-GH", "piecewise-PH-aGH", "piecewise-PH-GH",
"Cox-PH-aGH", "Cox-PH-GH", "spline-PH-aGH", "spline-PH-GH",
"ch-Laplace"),
interFact = NULL, derivForm = NULL, lag = 0, scaleWB = NULL,
CompRisk = FALSE, init = NULL, control = list(), ...)
jointModelBayes(lmeObject, survObject, timeVar,
param = c("td-value", "td-extra", "td-both", "shared-betasRE", "shared-RE"),
extraForm = NULL, baseHaz = c("P-splines", "regression-splines"),
transFun = NULL, densLong = NULL, lag = 0, df.RE = NULL,
estimateWeightFun = FALSE, weightFun = NULL, init = NULL,
priors = NULL, scales = NULL, control = list(), ...)







Database - Martins, Silva, Andreozzi (2016) Stat. Med.
network of 88 laboratories located in every state in Brazil during
2002–2006;
Sample: n = 4654 individuals;
Outcomes: CD4+T lymphocyte counts and survival time;
Covariates: age (<50=0, ≥50=1); gender (Female=0, Male=1);
prevoi (previous opportunistic infection at study entry=1, no
previous infection=0); region (the 27 states of Brazil); time;
Patients: 320 deaths. 88% between 15 and 49 years old; 60%
males. 61% no previous infection. Initial CD4 median: 245
cells/mm3 (men - 226 cells/mm3; women - 263 cells/mm3).
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CD4 - counting evolution
















































































































































































































































































































































































































































































































































































CD4 | bik,β1, σ2e ∼N (mikj , σ2)
mikj =β11 + β12tikj + β13t2ikj + β14t3ikj+
b1ik + b2iktikj + b3ikt2ikj + b4ikt3ikj+
β15genderik + β16ageik + β17PrevOIik
Survival specification




Qk|σ2Q ∼ ICAR(σ2Q), k = 1, . . . , 27
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• male, 31 years old, without previous opportunistic infection and
censored time 1645 days
• male, 29 years old, with previous opportunistic infection and
censored time 1508 days
Posterior median survival time: joint model improves the
survival estimates
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